Abstract
Association studies between Alpha-1-antichymotrypsin (ACT)-17(A>T) polymorphisms and Alzheimer’s disease (AD) susceptibility have shown conflicting results. In this investigation, we performed a meta-analysis to assess the purported associations. Subgroup analyses based on ethnicity (Caucasians, East-Asian and American mixed) were also performed including a total of 5,676 AD patients and 5,460 controls for ACT-17. Overall, allele contrast (A vs. T) of ACT -17 polymorphism produced significant results in the worldwide population [Pheterogeneity=0.01, random-effects (RE) odds ratio (OR) 1.12; 95% CI 1.04-1.21, P=0.003] and in the Caucasian population [Pheterogeneity=0.03, RE OR1.11 95% CI 1.01-1.24, P=0.04]. Meta-analyses of other genetic contrasts suggested that the A allele carriers are associated with increased susceptibility to AD in variant populations. No significant association was observed in the East-Asian subgroup analysis. In conclusion, ACT-17 variation presents a risk factor for AD in the worldwide population, especially in the Caucasian population.
Keywords: Abeta-peptide, Alpha-1-antichymotrypsin, Alzheimer’s disease, meta-analysis polymorphism, susceptibility
Current Alzheimer Research
Title:The Association of ACT -17 A/T Polymorphism with Alzheimer’s Disease: A Meta-Analysis
Volume: 10 Issue: 1
Author(s): Chao Dou, Jiyuan Zhang, Yang Sun, Xin Zhao, Qihan Wu, Chaoneng Ji, Shaohua Gu, Yi Xie and Yumin Mao
Affiliation:
Keywords: Abeta-peptide, Alpha-1-antichymotrypsin, Alzheimer’s disease, meta-analysis polymorphism, susceptibility
Abstract: Association studies between Alpha-1-antichymotrypsin (ACT)-17(A>T) polymorphisms and Alzheimer’s disease (AD) susceptibility have shown conflicting results. In this investigation, we performed a meta-analysis to assess the purported associations. Subgroup analyses based on ethnicity (Caucasians, East-Asian and American mixed) were also performed including a total of 5,676 AD patients and 5,460 controls for ACT-17. Overall, allele contrast (A vs. T) of ACT -17 polymorphism produced significant results in the worldwide population [Pheterogeneity=0.01, random-effects (RE) odds ratio (OR) 1.12; 95% CI 1.04-1.21, P=0.003] and in the Caucasian population [Pheterogeneity=0.03, RE OR1.11 95% CI 1.01-1.24, P=0.04]. Meta-analyses of other genetic contrasts suggested that the A allele carriers are associated with increased susceptibility to AD in variant populations. No significant association was observed in the East-Asian subgroup analysis. In conclusion, ACT-17 variation presents a risk factor for AD in the worldwide population, especially in the Caucasian population.
Export Options
About this article
Cite this article as:
Dou Chao, Zhang Jiyuan, Sun Yang, Zhao Xin, Wu Qihan, Ji Chaoneng, Gu Shaohua, Xie Yi and Mao Yumin, The Association of ACT -17 A/T Polymorphism with Alzheimer’s Disease: A Meta-Analysis, Current Alzheimer Research 2013; 10(1) . https://dx.doi.org/10.2174/1567205011310010009
DOI https://dx.doi.org/10.2174/1567205011310010009 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Bupropion HCL and Sleep in Patients with Depression
Current Psychiatry Reviews Hypersensitivity Reactions to Complementary and Alternative Medicine Products
Current Pharmaceutical Design Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Current Alzheimer Research Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Responses of Glial Cells to Stress and Glucocorticoids
Current Immunology Reviews (Discontinued) Principles and Applications of Diffuse Optical Imaging for the Brain
Current Medical Imaging Subtype Classification by Polymerase and Gag Genes of HIV-1 Iranian Sequences Registered in the NCBI GenBank
Current Proteomics Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke
Current Drug Targets - CNS & Neurological Disorders Treatment-resistant Late-life Depression: Challenges and Perspectives
Current Neuropharmacology Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimers Pathology in MCI and AD
Current Alzheimer Research Endothelial Dysfunction in Renal Failure: Current Update
Current Medicinal Chemistry Misoprostol Reverse Hippocampal Neuron Cyclooxygenase-2 Downstream Signaling Imbalance in Aluminum-Overload Rats
Current Alzheimer Research Conference Report: The American Association for the Advancement of Science (AAAS), 180th Annual Meeting Chicago, IL, USA Feb 13-17, 2014 “Meeting Global Challenges: Discoveries & Innovation”
CNS & Neurological Disorders - Drug Targets The Essential Mechanisms of Aging: What Have We Learnt in Ten Years?
Current Topics in Medicinal Chemistry Update on Statins: Hope for Osteoporotic Fracture Healing Treatment
Current Drug Targets Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events
Current Pharmaceutical Design Rashes, Sniffles, and Stroke: A Role for Infection in Ischemic Stroke of Childhood
Infectious Disorders - Drug Targets Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease
Current Alzheimer Research Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets